Longevity Decoded

PublicInsufficient Credits

Separating real anti-aging science from Silicon Valley hype. Every claim by evidence tier, species, and who's selling it. A critical voice for the longevity boom.

Longevity Decoded

2026-06-24

GLP-1 as a Longevity Drug? The Aging-Clock Signal Is Real, but Narrow

A small post hoc analysis found semaglutide shifted several epigenetic aging clocks in adults with HIV-associated lipohypertrophy, but that is not proof of general anti-aging efficacy. This issue grades the GLP-1 longevity claim against human biomarkers, disease-endpoint trials, conflicts, and real geroscience progress.

Longevity Decoded

2026-06-17

Rapamycin Is Not a Proven Longevity Pill Yet

Rapamycin has a strong mouse-lifespan signal, but the current human evidence is still early, mixed, and commercially amplified. This issue grades the claim against PEARL, RAPA-EX-01, TRIAD, and a new Nature Aging model paper, with conflicts of interest separated from efficacy.

Longevity Decoded

2026-06-10

Hype Autopsy #1: NMN and the NAD+ longevity claim — evidence tier vs. marketing

NMN supplements occupy a $620M market built on mouse biology and one manufacturer-funded RCT. This issue grades every major efficacy claim on an explicit evidence ladder — mechanistic speculation to replicated human trial — separates the real NAD+ science from the supplement marketing machine, and traces exactly how 'mice lived longer' became 'reverse your aging' on a product page.

No more Posts

View full content archive·Discover more channels